5PSQ-031 Pneumocystis carinii pneumonia prevention in lung transplantation: is atovaquone effective?

摘要

Pneumocystis carinii pneumonia (PCP) is an uncommon severe complication in immunocompromised patients. There is only one marketed treatment to prevent PCP: trimethoprime-sulfamethoxazole (TMP-SMZ). Due to side-effects (mainly neutropaenia), TMP-SMZ is sometimes replaced by off-label drugs. Notably, atovaquone has been studied in several conditions, but its effectiveness has never been assessed in lung transplantation.